Work

Neuroprotection of retinal ganglion cells in experimental glaucoma using a novel gene therapy construct AAV2 hSYN1-TrkB-2A-mBDNF in adult and old mice

Year: 2026
Type: article
Abstract: Glaucoma is a progressive neurodegenerative disease characterised by retinal ganglion cell (RGC) loss and irreversible vision impairment. Although intraocular pressure (IOP)-lowering therapies remain the clinical standard, they are insufficient to fully prevent disease progression, highlighting the need for strategies that directly protect RGCs. Gene therapy represents a promising approach to address this limitation by enabling sustained delivery of neuroprotective factors to vulnerable neuronal populations. The research in this thesis characterised adeno associated viral (AAV) promoter-mediated specificity to RGCs for neuroprotective gene therapy by comparing the transduction efficiency and specificity of a ubiquitous promoter, CAG, to a neuron-specific promoter, hSYN1. Immunohistochemistry confirmed that the hSYN1 promoter conferred higher specificity and better transduction expression in RGCs that the CAG promoter. The neuron-specific promoter, hSYN1, was chosen to deliver a novel neurotrophic signalling construct, AAV2 hSYN1-TrkB-2A-mBDNF, carrying brain derived neurotrophic factor (BDNF) in its mature formulation (mBDNF) as well as its receptor, TrkB, both known to be downregulated in glaucoma. Although IOP and age are the most significant risk factors for the development and progression of glaucoma, most experimental glaucoma research is performed in adult mice. Therefore, the research was performed in both adult and old mice using a model of experimental glaucoma (EG) where cross-linked hydrogels injected into the anterior chamber are used to elevate IOP. The research described in this thesis further evaluated the influence of treatment onset; pre- (three-weeks before), concomitant (zero-weeks), and delayed post- (three-weeks after) EG induction; on neuroprotective outcomes. Across experimental conditions, injection with the novel construct significantly improved RGC survival compared to sham-injected controls; however, neuroprotection was dependent on both timing and age, with earlier intervention and younger animals exhibiting greater preservation of RGCs. These findings highlight the importance of incorporating clinically relevant variables, including treatment timing and age, into preclinical study design to improve translational relevance. Gene therapy approaches that account for these factors may offer a more effective strategy for preserving vision in glaucoma.
Language: English
Subfield: Ophthalmology
Field: Medicine
Open Access status: green
OpenAlex ID: W7208272354
FWCI:
Cites: 447
Cited by:
Related to: 9